Anle138b is an oral, brain-penetrant, general inhibitor of protein aggregation. It was identified in a high-throughput screen for small-molecule inhibitors of α-synuclein and prion protein oligomerization. The compound is being developed for treatment of the rapidly progressing synucleinopathy multiple-system atrophy (MSA) and for Parkinson's disease (PD).
武漢永璨生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook，有助于交易順利完成！
武漢永璨生物